These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22682018)

  • 1. Management of bone metastases from advanced renal cell carcinoma.
    Khattak MA; Martin HL
    Eur J Cancer; 2012 Nov; 48(16):3123-5. PubMed ID: 22682018
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
    Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
    Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
    Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney cancer: SWITCHing inconsequential.
    Thoma C
    Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

  • 6. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
    Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
    Wolter P; Beuselinck B; Pans S; Schöffski P
    Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
    [No Abstract]   [Full Text] [Related]  

  • 9. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
    Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
    J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
    [No Abstract]   [Full Text] [Related]  

  • 10. [Not Available].
    Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
    Michaelson MD
    Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
    [No Abstract]   [Full Text] [Related]  

  • 12. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
    Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
    Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
    Manoukian GE; Tannir NM; Jonasch E; Qiao W; Haygood TM; Tu SM
    Clin Genitourin Cancer; 2011 Dec; 9(2):81-8. PubMed ID: 21958521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.
    Hird AE; Chow E; Ehrlich L; Probyn L; Sinclair E; Yip D; Ko YJ
    J Palliat Med; 2008 Oct; 11(8):1156-61. PubMed ID: 18980461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent scrotal hemangiomas during treatment with sunitinib.
    Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
    J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
    Rexer H
    Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E; Lanocita R; Procopio G
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract]   [Full Text] [Related]  

  • 18. [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
    Arima S; Shiroki R; Mori S; Maruyama T; Sasaki H; Kusaka M; Miyakawa S; Hayakawa K; Hoshinaga K
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):660-5. PubMed ID: 18697474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)].
    Rexer H
    Urologe A; 2012 Feb; 51(2):252-3. PubMed ID: 22331073
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G; Autorino R
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.